CRBU Stock — Caribou Biosciences, Inc.: Metrics

Market overview

2 metrics

Share price

$1.60

Market cap

$171.53M

Price action

19 metrics

Price change (1W)

-3.0%

Price change (30D)

+1.9%

Price change (3M)

-20.0%

Price change (6M)

-11.1%

Price change (YTD)

+0.6%

Price change (1Y)

-14.9%

Trailing year

Price change (5Y)

-94.4%

52-week high

$2.84

52-week low

$1.39

Change from 52-week high

-43.7%

Change from 52-week low

+15.1%

Annualized volatility

73.1%

Beta

2.3

RSI (14D)

47.6

Price vs SMA 50

-3.7%

Price vs SMA 200

-10.9%

Avg volume (3M)

1.71M

Relative volume

0.5

Average dollar volume

$2.93M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

107.21M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

17.1×

reciprocal yield 5.9%

P / book

1.7

reciprocal yield 57.2%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-60.3%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-07

Profitability

9 metrics

Gross margin

—

Operating margin

-1,090.9%

Trailing 12 months

Net margin

-1,030.4%

Gross profit (TTM)

—

Operating profit (TTM)

−$109.47M

Net income (TTM)

−$103.40M

Trailing 12 months

Diluted EPS (TTM)

$-1.08

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-2.41

Growth

11 metrics

Revenue growth YoY

-43.8%

Year over year

Net income growth YoY

—

Revenue (TTM)

$10.04M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+8.6%

Year over year · more shares

Revenue CAGR (3Y)

-7.0%

Revenue CAGR (5Y)

-2.0%

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-105.4%

Return on assets

-72.4%

Debt / equity

—

Current ratio

6.5

EBITDA (TTM)

−$106.89M

Free cash flow (TTM)

—

Quick ratio

6.5

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$26.19M

Total assets

$142.77M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$95.78M

Capital expenditures (TTM)

—

R&D (TTM)

$85.77M

SG&A (TTM)

—

Stock compensation (TTM)

$10.50M

R&D / revenue

854.7%

Stock compensation / revenue

104.7%

Ownership (13F)

3 metrics

13F filers

137

13F filer change QoQ

0

Institutional ownership

45.4%

Short interest

3 metrics

Short interest

11.6%

Latest settlement · 12.0 days to cover

Days to cover

12.0d

Short-squeeze score

65 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

CRBU · Caribou Biosciences, Inc.

CRBU metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search